Pharmafile Logo

Scripps

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Mtech Access

- PMLiVE

NICE recommends better targeting of antibiotics for suspected sepsis

It is hoped that the new guidance will reduce the risk of antibiotic resistance by ensuring antibiotics are targeted to those at the greatest risk

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

WHO publishes new infodemic management tools for pandemic preparedness

The taxonomy will support pandemic planning for respiratory pathogen disease events

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

NIHR launches new framework to highlight health progress outcomes

Over 400 partners and stakeholders collaborated to develop the new framework

- PMLiVE

UKHSA secures UK-based vaccine deal for future influenza pandemics

CSL Sequiris will be ready to produce over 100 million influenza pandemic vaccines

- PMLiVE

CDC provides $262.5m to create national network for infectious diseases

The OADMN aims to improve responses to outbreaks and prevent future pandemics

- PMLiVE

CDC awards over $23m to Johns Hopkins Center for Health Security project

The five-year grant will be used to help launch a new epidemic preparedness project

- PMLiVE

CureVac advances ‘promising’ seasonal flu mRNA vaccine to phase 2 development

The mid-stage study of the candidate is expected to begin in the fourth quarter of 2023

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links